Record mula sa primary source
Xilio dosed the first patient in the Phase 1 portion of its Phase 1/2 trial of XTX501 (PD-1/masked IL-2 bispecific) in metastatic NSCLC and select solid tumors. The company plans to report initial Phase 1 data in Q4 2027. This is the first clinical update for this asset.
EX-99.1 2 xlo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Xilio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Pipeline and Business Updates Dosed first patient in Phase 1/2 clinical trial for XTX501, a potential best-in-class PD-1/masked IL-2 bispecific, for patients with metastatic NSCLC, and plan to report initial Phase 1 data in the fourth quarter of 2027 Advancing XTX602, a dual-masked CLDN18.2-targeting multi-specific TCE with co-stimulation, and XTX701, a masked PSMAxSTEAP1-targeting multi-specific TCE with co-stimulation, toward planned IND applications in the fourth quarter of 2027 WALTHAM, Mass., November 10, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-on